Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS

Neurology

Volumn 81, Issue 1, 2013, Pages 76-83

  Garcia Martin, Elena ^a,c   Rodriguez Mena, Diego ^a,c   Herrero, Raquel ^a,c   Almarcegui, Carmen ^a,c   Dolz, Isabel ^a,c   Martin, Jesus ^b,c   Ara, Jose R ^b,c   Larrosa, Jose M ^a,c   Polo, Vicente ^c   Fernández, Javier ^a,c   Pablo, Luis E ^a,c  

^a Neurophysiology Department   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; ARTICLE; CLINICAL EVALUATION; COLOR VISION; CONTRAST SENSITIVITY; DIPLOPIA; DISABILITY; DISEASE DURATION; DISTRESS SYNDROME; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE QUALITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROOPHTHALMOLOGY; OBSERVATIONAL STUDY; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; OUTCOME ASSESSMENT; PERIMETRY; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTION ERROR; RETINAL NERVE FIBER LAYER THICKNESS; SEXUAL FUNCTION; SIGNAL NOISE RATIO; VISION; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL SYSTEM;

EVOKED POTENTIALS, VISUAL; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBERS; QUALITY OF LIFE; QUESTIONNAIRES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS;

EID: 84881241897     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318299ccd9     Document Type: Article

References (30)

1. Khan F, Pallant JF, Pallant JI, Brand C, Kilpatrick TJ. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:1033-1038.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
3. Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: II: quality of life. Can J Neurol Sci 1998;25:31-38.
4. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098-1103.
5. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. In: Goodkin DE, Rudick RA, eds. Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives. London: Springer; 1996:223-250.
6. Miller DM, Rudick RA, Baier M, et al. Factors that predict health-related quality of life in patients with relapsingremitting multiple sclerosis. Mult Scler 2003;9:1-5.
7. Iriarte J, Subira ML, Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000;6:124-130.
8. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002;288:3027-3034.
9. Garcia-Martin E, Pueyo V, Almarcegui C, et al. Risk factors for progressive axonal degeneration of the retinal nerve fibre layer in multiple sclerosis patients. Br J Ophthalmol 2011;95:1577-1582.
10. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007;69:1603-1609.
11. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007;68:1488-1494.
12. Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;36(suppl):42-46.
13. Garcia-Martin E, Pueyo V, Martin J, et al. Progressive changes in the retinal nerve fiber layer in patients with multiple sclerosis. Eur J Ophthalmol 2010;20:167-173.
14. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57:1319-1324.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58:840-846.
16. Herrero R, Garcia-Martin E, Almarcegui C, et al. Progressive degeneration of the retinal nerve fiber layer in patients with multiple sclerosis. Invest Ophthalmol Vis Sci 2012; 53:8344-8349.
17. Schuman JS, Pedut-Kloizman T, Hertzmark E, et al. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmology 1996;103: 1889-1898.
18. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life for multiple sclerosis. Qual Life Res 1995;4:187-206.
19. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205.
20. Meyers AR, Gage H, Hendricks A. Health-related quality of life in neurology. Arch Neurol 2000;57:1224-1227.
21. Solari A, Fillipini G, Mendoz L, et al. Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry 1999;67:158-162.
22. Almarcegui C, Dolz I, Pueyo V, et al. Correlation between functional and structural assessments of the optic nerve and retina in multiple sclerosis patients. Neurophysiol Clin 2010;40:129-135.
23. Saidha S, Sotirchos ES, Oh J, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. Arch Neurol Epub 2012 Oct 1.
24. Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci 2010;51:2770-2777.
25. Pueyo V, Ara JR, Almarcegui C, et al. Subclinical atrophy of the retinal nerve fiber layer in multiple sclerosis. Acta Ophthalmol 2010;88:748-752.
26. Pueyo V, Martin J, Fernandez FJ, et al. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Mult Escler 2008;14:609-614.
27. Aymerich M, Guillamón I, Perkal H, et al. Validación de la versión Española del MSQOL-54. Neurología 2005;20:480. 28.
28. Alonso J, Prieto L, Antó JM. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin 1995;104:771-776. 29.
29. Gundogan FC, Demirkaya S, Sobaci G. Is optical coherence tomography really a new biomarker candidate in multiple sclerosis? A structural and functional evaluation. Invest Ophthalmol. Invest Ophthalmol Vis Sci 2007;48:5773- 5781. 30.
30. Garcia-Martin E, Pueyo V, Pinilla I, Ara JR, Martin J, Fernandez J. Fourier-domain OCT in multiple sclerosis patients: reproducibility and ability to detect retinal nerve fiber layer atrophy. Invest Ophthalmol Vis Sci 2011;52: 4124-4131.